Octagam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Octagam, is an immunoglobulin presented as a sterile solution for intravenous use. It provides pooled IgG antibodies to replace deficient immunoglobulins and to modulate immune activity in patients with primary and secondary immune deficiencies.

GNH USA supplies Octagam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers cold‑chain logistics for biologic products.

Octagam is used in several immune‑related conditions where replacement or modulation of IgG is required.

- Primary immunodeficiency diseases: restores deficient IgG levels and reduces infection risk. - Secondary immunodeficiency (e.g., after chemotherapy): supports immune function during immunosuppression. - Immune thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. - Kawasaki disease: reduces coronary artery inflammation in pediatric patients. - Guillain‑Barré syndrome: accelerates recovery by dampening autoimmune nerve damage.

Adverse reactions may occur with any intravenous immunoglobulin product.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever or chills: typically during or shortly after infusion. - Nausea or vomiting: occasional gastrointestinal upset. - Fatigue: general feeling of tiredness post‑infusion. - Mild rash or urticaria: skin irritation at infusion site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: clot formation in veins or arteries. - Renal impairment: acute kidney injury, especially with high‑dose regimens. - Hemolysis: destruction of red blood cells leading to anemia. - Aseptic meningitis: severe headache with neck stiffness and photophobia.

Octagam should be administered with careful consideration of patient history and clinical status.

- Assess IgG levels: confirm deficiency before initiating therapy. - Monitor for infusion reactions: observe patients during and after infusion. - Evaluate renal function: avoid use in patients with pre‑existing kidney disease. - Screen for thrombotic risk: consider history of clotting disorders. - Avoid in patients with known IgA deficiency and anti‑IgA antibodies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octagam may interact with other medications that affect immune function or coagulation.

Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy and increase infection risk. - High‑dose aspirin or anticoagulants: heightened risk of bleeding complications.

Moderate Interactions (Monitor Closely): - Corticosteroids: may augment immunosuppressive effects. - Rituximab or other B‑cell depleting agents: potential additive immunosuppression. - Diuretics: monitor fluid balance due to infusion volume. - ACE inhibitors: watch for increased risk of hypotension during infusion.